Captaru
  • Grants
  • Volunteers
  • Community
  • Pricing
  • About
    Who We AreOur PartnersJobs
  • Transparency
  • Blog
  • Contact
Captaru Logo

Starting from what we can do and think, our strength is bringing our own and third-party social projects to life.

proyectos@captaru.org
CAPTARU
  • ABOUT US
  • PROJECTS
  • Grant management
  • NGO platform
  • EU funding
  • TRANSPARENCY
  • CONTACT
FOLLOW US
  • Facebook
  • Twitter
  • LinkedIn
  • Youtube
Preferred source on Google
JOIN OUR NEWSLETTER AND NEVER MISS AN OPPORTUNITY
Legal NoticeDisclaimerCookie PolicyPrivacy StatementSubscription Terms

Fundación Plaza de Castilla, CIF G84070945, registered at Serrano Anguita 13, 28004 Madrid.

CAPTARU IS A PROJECT DEVELOPED WITH PASSION BY FUNDACIÓN PLAZA DE CASTILLA © 2026 ALL RIGHTS RESERVED

Back to list
Start a proposal with Captaru
🇺🇸GRANTS_GOVOPENGRANT375 days left

First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)

🏛 GRANTS_GOV · 📍 US

Total budget

Not specified

OPENING

Nov 26, 2024

CLOSING

Oct 15, 2027

Category

Health

Description

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs, or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase II studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The NOFO also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding for further clinical development as FDA-approved treatments. A key aspect of this NOFO is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.

Official source

View official source ↗

Eligible beneficiaries

  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Small businesses
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Special district governments
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Public and State controlled institutions of higher education
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • County governments
  • Independent school districts
  • City or township governments
  • Native American tribal governments (Federally recognized)
  • Public housing authorities/Indian housing authorities
  • For profit organizations other than small businesses
  • Private institutions of higher education
  • State governments

Related calls

  • Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
  • Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
  • Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
  • Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
  • Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)
  • Advancing Research on Empirically-Supported Interventions for Older Adults Living with Serious Mental Illness (SMI) (R01 Clinical Trial Optional)
See all open grants